摘要
目的:探讨人工二尖瓣膜成形术联合利奈唑胺治疗老年感染性心内膜炎的临床效果及安全性。方法:选取2015年5月—2017年3月我院收治的60例老年感染性心内膜炎患者为研究对象,按随机数字表法分为对照组和观察组,各30例。对照组采用利奈唑胺(6 g,bid)治疗,观察组在对照组基础上联合人工二尖瓣膜成形术治疗,比较两组心功能、炎症因子水平及并发症发生情况。结果:治疗后观察组左心射血分数(LVEF)水平低于对照组,左室收缩末期内径(LVESD)及左室收缩末期容积(LVESV)水平高于对照组(P<0.05);两组治疗前炎症因子水平比较,差异无统计学意义(P>0.05);治疗后观察组超敏C反应蛋白(hs-CRP)、红细胞沉降率(ESR)、降钙素原(PCT)水平均低于对照组(P<0.05);观察组并发症发生率高于对照组,差异有统计学意义(P<0.05)。结论:利奈唑胺联合人工二尖瓣膜成形术治疗老年感染性心内膜炎效果理想,能改善炎症因子水平,但不能降低并发症发生率。
Objective: To investigate the clinical efficacy and safety of artificial mitral valvuloplasty combined with linezolid in the treatment of senile infective endocarditis. Methods: Sixty elderly patients with infective endocarditis admitted to our hospital from May 2015 to March 2017 were selected as study subjects and randomly divided into control group and observation group, 30 cases in each group. The patients in the control group were treated with linezolid(6 g, bid). The patients in the observation group were treated by artificial mitral valvuloplasty on the basis of the control group. Cardiac function, levels of inflammatory factors and complications were compared between the two groups. Results: The level of left ventricular ejection fraction(LVEF) in the observation group was lower than that in the control group, and the levels of left ventricular end-systolic diameter(LVESD) and left ventricular end-systolic volume(LVESV) in the observation group were higher than those in the control group(P<0.05). There was no significant difference in the levels of inflammatory factors between the two groups before treatment(P>0.05). After treatment, the levels of high-sensitivity C-reactive protein(hs-CRP), erythrocyte sedimentation rate(ESR) and procalcitonin(PCT) in the observation group were lower than those in the control group(P<0.05). The incidence of complications in the observation group was significantly higher than that in the control group(P<0.05). Conclusion: Linezolid combined with artificial mitral valvuloplasty has an ideal effect in the treatment of senile infective endocarditis, which can improve the levels of inflammatory factors, but cannot reduce the incidence of complications.
出处
《中国执业药师》
CAS
2018年第9期18-21,共4页
China Licensed Pharmacist
